Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00896480
Recruitment Status : Completed
First Posted : May 11, 2009
Last Update Posted : October 15, 2015
Information provided by (Responsible Party):

Brief Summary:
The clinical objective of this clinical trial is to examine the clinical activity in terms of tumor response and time to treatment failure of the immunotherapeutic product GSK2132231A when given to patients with unresectable and progressive metastatic cutaneous melanoma. The safety of the treatment will also be assessed just as its immunogenicity in terms of the humoral and cellular immune response induced by the GSK2132231A immunotherapeutic. Translational research objectives are to assess the effects of the study treatment in terms of various biological variables.

Condition or disease Intervention/treatment Phase
Melanoma Biological: Immunotherapeutic GSK2132231A Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Activity, Safety and Immunogenic Properties of Cancer Immunotherapeutic GSK2132231A in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma
Study Start Date : May 2009
Actual Primary Completion Date : November 2014
Actual Study Completion Date : November 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Single group
Patients will receive a treatment consisting of 24 injections of the experimental GSK2132231A immunotherapeutic
Biological: Immunotherapeutic GSK2132231A
Administration by intramuscular injection
Other Name: MAGE-A3 ASCI

Primary Outcome Measures :
  1. Tumor response defined as objective response (complete or partial), stable disease or mixed response [ Time Frame: After the concluding visit of the last patient ]
  2. Time to treatment failure defined as the interval from the first administration of the study treatment until the patient is withdrawn from treatment [ Time Frame: After the concluding visit of the last patient ]
  3. Occurrence of Grade 3 or 4 adverse events possibly related to the study treatment [ Time Frame: After the concluding visit of the last patient ]
  4. Occurrence of serious adverse events [ Time Frame: After the concluding visit of the last patient ]
  5. Occurrence of adverse events [ Time Frame: After the concluding visit of the last patient ]
  6. Immunogenicity [ Time Frame: At specified time points during the immunization period (20 assessments per patient) and after the concluding visit of the last patient ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. The patient (male or female) has histologically proven, measurable metastatic cutaneous melanoma in one of the following stages according to the American Joint Committee on Cancer classification of 2002:

    • Stage III in transit, or
    • Stage III unresectable, or
    • Stage IV M1a.
  2. There has been documented progression of the patient's disease within the 12 weeks before the first administration of study treatment.
  3. The patient presents at screening with at least 3 tumor lesions of diameter >= 0.5 mm.
  4. Written informed consent has been obtained from the patient before the performance of any protocol-specific procedure.
  5. The patient is >= 18 years of age at the time of signature of informed consent.
  6. The patient's tumor shows expression of MAGE-A3 gene in at least one of the two tumor biopsies performed at baseline.
  7. The patient's ECOG performance status is 0 or 1.
  8. The patient has normal organ functions, as assessed by standard laboratory criteria.
  9. If the patient is female, she must be of non-childbearing potential, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to administration of study treatment, have a negative pregnancy test and continue such precautions during the entire study treatment period and for 2 months after completion of the treatment injection series.
  10. In the view of the investigator, the patient can and will comply with the requirements of the protocol.

Exclusion Criteria:

  1. The patient has at any time received systemic (bio)-chemotherapy
  2. The patient is scheduled to receive any anti-cancer specific treatment, including radiotherapy, immunotherapy, chemotherapy and immunomodulating agents.
  3. The patient requires concomitant treatment with systemic corticosteroids, or any other immunosuppressive agents.
  4. The patient has received any cancer immunotherapeutic containing a MAGE A3 antigen or any cancer immunotherapeutic for his/her metastatic disease.
  5. Use of any investigational or non-registered product (drug or vaccine) other than the study treatment within the 30 days preceding the first dose of study treatment, or planned use during the study period.
  6. The patient has (or has had) previous or concomitant malignancies at other sites, except effectively treated malignancy that is considered by the investigator highly likely to have been cured.
  7. History of allergic disease or reactions likely to be exacerbated by any component of the study investigational product.
  8. The patient has an autoimmune disease such as, but not limited to, neuroinflammatory autoimmune diseases, systemic lupus erythematosus, and inflammatory bowel disease
  9. The patient has a family history of congenital or hereditary immunodeficiency.
  10. The patient is known to be positive for the human immunodeficiency virus (HIV).
  11. The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent, or to comply with the study procedures.
  12. The patient has concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk.
  13. For female patients: the patient is pregnant or lactating.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00896480

GSK Investigational Site
Brussels, Belgium, 1200
GSK Investigational Site
Brussel, Belgium, 1090
GSK Investigational Site
Bruxelles, Belgium, 1180
GSK Investigational Site
Liège, Belgium, 4000
GSK Investigational Site
Wilrijk, Belgium, 2610
GSK Investigational Site
Yvoir, Belgium, 5530
GSK Investigational Site
Caen, France, 14033
GSK Investigational Site
Lille, France, 59037
GSK Investigational Site
Paris Cedex 10, France, 75475
GSK Investigational Site
Reims, France, 51092
GSK Investigational Site
Villejuif, France, 94805
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline

Responsible Party: GlaxoSmithKline Identifier: NCT00896480     History of Changes
Other Study ID Numbers: 111473
First Posted: May 11, 2009    Key Record Dates
Last Update Posted: October 15, 2015
Last Verified: December 2014

Keywords provided by GlaxoSmithKline:
ASCI (Antigen-Specific Cancer Immunotherapeutic)
Cancer immunotherapeutic
Malignant melanoma

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas